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ABSTRACT
Objective: The COVID-19 pandemic, caused by the acute respiratory syndrome-coronavirus 2 
(SARS-CoV-2), remains an ongoing public health challenge. Although males are affected 
slightly more than females, the impact of SARS-COV-2 on male reproductive system remains 
unclear. This systematic review aims to provide a concise update on the effects of COVID-19 on 
male reproductive health, including the presence of viral RNA in semen, and the impact on 
semen quality, testicular histology, testicular pain and male reproductive hormones. The global 
health is fronting an immediate as well as impending threat from the novel coronavirus (SARS- 
CoV-2) causing coronavirus disease (COVID-19), that inflicts more males than females. Evidence 
suggest that male reproductive system is susceptible to this viral infection. However, there are 
still several pertinent queries that remain to be fully explained regarding the mechanism in 
testicular SARS-CoV-2 dynamics and the exact mode of its actions. Thus, the present systematic 
review aims to provide a concise update on the effects of coronavirus disease 2019 (COVID-19) 
on male reproduction..
Methods: A systematic review was conducted according to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses guidelines searching the PubMed database. Eligibility 
for inclusion were original human studies evaluating the impact of COVID-19 on male repro-
ductive health. Specific outcomes required for inclusion were at least one of the following: i) 
seminal detection of mRNA virus, or evaluation of ii) semen analysis, iii) testicular histology or 
ultrasonography, iv) testicular clinical symptoms and/or v) male reproductive hormones in 
COVID-19-positive patients.
Results: Of 553 retrieved articles, 25 met the inclusion criteria. This included studies primarily 
investigating the presence of viral RNA in semen (n = 12), semen quality (n = 2), testicular 
histology (n = 5), testicular pain (n = 2) and male reproductive hormones (n= 4). Results show 
little evidence for the presence of viral RNA in semen, although COVID-19 seems to affect 
seminal parameters, induce orchitis, and cause hypogonadism. Mortality cases suggest severe 
histological disruption of testicular architecture, probably due to a systemic and local repro-
ductive tract inflammatory response and oxidative stress-induced damage.
Conclusions: Clinical evaluation of the male reproductive tract, seminal parameters and 
reproductive hormones is recommended in patients with current or a history of COVID-19, 
particularly in males undergoing fertility treatment. Any long-term negative impact on male 
reproduction remains unexplored and an important future consideration.
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Introduction
The coronavirus disease 2019 (COVID-19) is caused by 
the severe acute respiratory syndrome-coronavirus-2 
(SARS-CoV-2) [1,2], which is a highly transmissible cor-
onavirus (CoV) first identified in 2019. COVID-19 has 
subsequently emerged as a global pandemic and is 
a significant threat to public health and safety [2]. On 
the 17 March 2021, >120 million confirmed cases were 
reported, along with >2.5 million deaths globally [3]. 
As part of the CoV family, SARS-CoV-2 is genetically 
50% similar to Middle East Respiratory Syndrome 
(MERS)-CoV, 79.5% similar to SARS-CoV-1, and 96.5% 
similar to Bat-CoV [4–6]. However, due to its high 
transmission rate, SARS-CoV-2 is considered a more 
significant public health threat compared to SARS- 
CoV-1 and MERS-CoV [6].
The SARS-CoV-2 virus gains access to human cells 
through binding to cellular angiotensin-converting 
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enzyme 2 (ACE2) receptors via the receptor-binding 
domain as part of the spike (S) protein. This further 
requires priming by cellular transmembrane protease, 
serine 2 (TMPRSS2) [7,8]. Following infection through 
exposure to respiratory droplets, the incubation period 
is usually 3–7 days [8]. The most frequent symptoms 
reported include fever (>75%), cough (>60%), fatigue 
(>25%), dyspnoea (>20%) and sputum production 
(>18.0%). Other less frequent but common symptoms 
include anorexia, myalgia, pharyngitis, rhinitis and 
diarrhoea [9–11]. COVID-19 pathophysiology is consid-
ered a two-phase disease. The first phase is charac-
terised by increased viral transmission rates and 
replication, particularly through the respiratory tract 
due to the high expression of ACE2 and TMPRSS2. 
Phase 2 is a host-specific (including gender- and age- 
specific) characterised by a hyperinflammatory 
response, hypercytokinaemia and collateral tissue 
damage that may result in acute respiratory distress 
and systemic failure [7,8]. Increased risk for phase 2 
complications includes older age, obesity, hyperten-
sion, diabetes and chronic respiratory disease [12].
Although epidemiological data suggests that men 
may have an increased risk of COVID-19-related mor-
bidity and mortality [13–19], the potential impact on 
male reproduction and any mechanisms remain poorly 
understood. Numerous review articles have postulated 
the potential of SARS-CoV-2 to infect male reproduc-
tive tissues due to the presence of ACE2 receptors. This 
has led to the hypothesis that SARS-CoV-2 may gain 
access to the reproductive tract, may be sexually trans-
mitted, and that COVID-19 may directly or indirectly 
impair reproductive function and/or disrupt the 
hypothalamus-pituitary-testis axis [20–25].
As COVID-19 remains an ongoing public health 
challenge, there is an increasing number of studies 
investigating its impact on testicular functions and 
reproductive hormones. Therefore, the present sys-
tematic review aims to provide a concise update on 
the effects of COVID-19 on male reproductive health. 
This will focus on presence of viral RNA in semen, 
semen quality, testicular histology, testicular pain and 
male reproductive hormones.
Methods
The literature search was conducted based on the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [26]. The PubMed 
database was searched (last updated search on 
7 February 2021) using the following keyword string 
adapted from Khalili et al. (2020) [27]: (‘severe acute 
respiratory syndrome–coronavirus 2’ OR ‘severe acute 
respiratory syndrome coronavirus 2’ OR ‘COVID-19’ OR 
‘SARS-CoV-2’ OR ‘SARS CoV2’ OR ‘SARS CoV 2’) AND 
(‘semen’ OR ‘sperm*’ OR ‘seminal’ OR ‘testes’ OR ‘testi-
cular’ OR ‘male fertil*’ OR ‘male infertil*’ OR ‘epididy-
mis’ OR ‘prostate’ OR ‘testosterone’ OR ‘LH’ OR ‘FSH’ OR 
‘cryopreservation’). Inclusion criteria were original 
human studies evaluating the impact of COVID-19 on 
male reproductive health. Specific outcomes required 
for inclusion were at least one of the following: i) 
seminal detection of mRNA virus, ii) semen analysis, 
iii) testicular histology or ultrasonography (US), iv) 
Articles identified through PubMed 
database
(n=553)
Full-text articles assessed for eligibility
(n=30)
Articles excluded on title and abstract 
screening
(n=523)
Articles excluded on eligibility criteria
(Review Studies = 3)
(Not COVID-19 cohort = 2)
Articles included
(n=25)
Figure 1. PRISMA flow diagram of systematic search.
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testicular clinical symptoms, and/or v) male reproduc-
tive hormones (testosterone, LH and/or FSH). Exclusion 
criteria were narrative or systematic reviews, and meta- 
analysis, pre-clinical studies and non-English studies. 
Retrieved articles were manually screened based on 
the titles and abstracts, and subsequently verified for 
eligibility by two authors (P.S. and K.L.), and any dis-
putes were settled by a third author (A.A.).
Results
A total of 553 articles were retrieved following the 
PubMed database extraction. Of these, 523 articles 
were removed following screening of titles and 
abstracts. A total of 30 full-text articles were assessed 
for eligibility, with five articles removed as they were 
review articles (three) or not a COVID-19 cohort (two). 
Therefore, a total of 25 articles were included into this 
review (Figure 1). These were further classified based 
on the primary objective of the study: presence of viral 
RNA in semen (12) (Table 1), semen quality (two) (Table 
2), testicular histology (five) (Table 3), testicular pain 
(two) (Table 4), and male reproductive hormones (four) 
(Table 5)
SARS-CoV-2 in human semen
The results of this review retrieved 12 studies that 
primarily investigated the presence of SARS-CoV-2 
RNA in human seminal fluid, with only two studies 
detecting the presence of the virus in semen (Table 1).
In 38 male patients (aged >15 years) that tested 
positive for COVID-19 at Shangqiu Municipal Hospital, 
SARS-CoV-2 RNA was detected in the semen samples 
of four acute stage patients and two recovery phase 
patients [28]. Gacci et al. [29] (2021) reported only one 
patient in a cohort of 43 sexually active men recovered 
from COVID-19 to have evidence of SARS-CoV-2 RNA in 
seminal fluid, who subsequently tested negative on 
a nasopharyngeal test the next day. In an additional 
study that included a sub-analysis investigating the 
impact of COVID-19 on semen analysis in 12 SAR2- 
CoV-2-positive patients, Ma et al. [30] (2021) reported 
the presence of the viral RNA in one case of mild 
infection, with the remaining 11 cases (moderate infec-
tion) being negative. Achua et al. [31] (2021) reported 
testicular viral spike protein particles in one out of four 
COVID-19-positive case autopsies on microscopy, and 
from a sample obtained from one alive positive COVID- 
19 patient.
The remaining studies did not detect the virus in 
seminal fluid. Kayaaslan et al. [32] (2020) investigated 
semen of 16 hospitalised patients (median age 
33.5 years) with SARS-CoV-2 infection confirmed on 
nasopharyngeal swabs in a cross-sectional cohort 
study, with 11 semen samples collected within 1 day 
of a positive diagnosis and all samples within 7 days. In 
these acutely ill patients, no viral RNA was detected in 
the semen. Similarly, no viral RNA detection in seminal 
fluid was reported in a case-controlled study of 74 men 
(median age 34 years) who had been hospitalised and 
confirmed positive for COVID-19 and subsequently 
were recovering. The authors reported that 14.9% 
were asymptomatic (mild), 41.9% were classified as 
moderate, and 43.2% had severe pneumonia [33]. In 
34 Chinese male patients (median age 37 years) reco-
vering from COVID-19, the virus was not detected at 
a median of 31 days after a confirmed nasopharyngeal 
diagnosis [34]. Another case-controlled cross-sectional 
study that investigated confirmed and probable 
COVID-19 cases before (10) and after treatment (10) 
compared to control (10) (mean [SD] age for entire 
cohort 37.2 [8.6] years) also found no evidence of 
SARS-CoV-2 RNA in seminal fluid [35]. Similarly, Song 
et al. [36] (2020) reported no viral RNA in semen of 12 
men (aged 22–38 years) recovering from COVID-19 
(two negative tests following a positive diagnosis) in 
Wuhan, China, where 11 patients had mild-to- 
moderate symptoms and one was asymptomatic. In 
a case-controlled cohort study that included 16 
patients recovering from COVID-19 (mean [SD] age 
42.2 [9.9] years), two patients with acute COVID-19 
and 14 control patients (mean [SD] age 33.4 [13.1] 
years) that were negative for SARS-CoV-2, no viral 
RNA was found in seminal fluid in any participant 
[37]. A small cohort of six men (aged 28–45 years) 
that were diagnosed with COVID-19 based on symp-
toms and a positive nasopharyngeal swab were nega-
tive for seminal viral RNA, while still positive for saliva 
and nasal swab viral RNA [38]. In a cohort of nine Italian 
men (median age 42 years) positive for nasopharyn-
geal swab and a diagnosis of mild (eight) or asympto-
matic (one) COVID-19 that did not require 
hospitalisation, none of the semen samples showed 
the presence of viral RNA [39]. Similarly, no viral RNA 
was identified in seminal fluid of 23 men (age 20– 
62 years) within the acute phase or convalescence 
period of COVID-19. The median time from diagnosis 
to the semen sample was 32 days. Among these 23 
men, the virus had been cleared in 11 of them at time 
of semen analysis, with 12 men having positive viral 
RNA in sputum or faecal specimens [40]. This is sup-
ported by a case study by Paoli et al. [41] (2020) on 
a 31-year-old man presenting with fever, myalgia, 
anosmia, and ageusia, tested positive for SARS-CoV-2 
on pharyngeal swab, yet also tested negative for viral 
RNA in semen and urine 8 days later. Furthermore, in 
a study that investigated testicular samples on 
autopsy, Flaifel et al. [42] (2021) reported no evidence 
of viral RNA in testes of 10 patients who had 
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Table 2. Available literature investigating SARS-CoV-2 infection on semen quality.
Reference
Study 

















Decreased sperm concentration 
compared to controls; in the 
recovering patients, 39.1% had 
oligozoospermia and 60.9% had 
increased leucocytes; increased 
seminal levels of IL-6, TNF-α, and 
MCP-1 compared to control
Autopsied testicular and epididymal 
samples showed oedema, 
congestion and exudation of 
erythrocytes; thinning of 
seminiferous tubules and increased 
number of seminiferous apoptotic 
cells was observed in the autopsied 
testes; increased concentration of 
CD3+ and CD68+ in the interstitial 
cells of testicular tissue and the 
presence of IgG within seminiferous 
tubules of autopsied testes.
44 Case- 
controlled 
longitudinal study COVID-19 
recovering 
patients (84)
Healthy men (105) Significant impairments in semen 
volume, sperm concentration 
progressive motility, sperm 
morphology compared to control; 
significantly higher levels of seminal 
plasma ACE2 enzymatic activity, IL- 
1β, IL-6, IL-8, IL-10, TGF-β, TNF-α, 
IFN-α, IFN-γ, ROS, caspase-8, 
caspase-9, and caspase-3 activity 
and lower levels of SOD activity 
compared to control group.
–
Table 3. Available literature investigating SARS-CoV-2 infection on testicular histology and/or ultrasonography.












Impaired spermatogenesis in 3 COVID-19- 
positive cases; viral spike protein particles 
observed in testis of one COVID-19-positive 
autopsy case, associated with infiltration of 
macrophages and leucocytes; reduced 
expression of ACE2 receptors in testes of 
COVID-19 patients with normal 
spermatogenesis compared to COVID-19 
















Acute testicular injury reported that is related to 
oxidative stress (spermatocytes elongation 
and sloughing with Sertoli cell swelling) 
compared to chronic damage in controls 
(decreased spermatogenesis and Leydig cells)
No SARS-CoV-2 RNA detected 








Uninfected controls (3) Morphological disruptions of testes reported. GCs 
degeneration and sloughing in seminiferous 











Uninfected controls (5) Sertoli cell swelling, vacuolisation and 
detachment from basement membranes; 
significantly reduced Leydig cells compared to 
control; interstitial oedema and mild 
inflammatory infiltrates; no microscopy 
detection of viral particles
SARS-Cov-2 RNA detected in 









– Orchitis, epididymitis, or epididymo-orchitis in 
22.5% of patients with COVID-19, associated 
with thickened tunica albuginea and increased 
vascular flow as common findings
–
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Table 4. Available literature investigating SARS-CoV-2 infection on male reproductive clinical symptoms.















Testicular pain prevailed in 10.98% 
patients (n= 91), with one case of 
clinical epididymo-orchitis reported
No difference for neutrophil count, 
lymphocyte count, CRP, D-dimers or 
duration of COVID-19 infection between 
groups
49 Case study 42-year-old- 
male patient 
(1)
– Presented with abdominal and 
testicular pain without respiratory 
symptoms
–
Table 5. Available literature investigating SARS-CoV-2 infection on male reproductive hormones.
Reference
Study 
design Cohort (n) Control (n) Hormones Other findings







Age-matched control (273) Decreased testosterone and increased LH; 
decreased testosterone:LH ratio that had 






SDF in 33.3% of 
11 cases; SARS- 
CoV-2 RNA 
detected in 
semen from 1 
patient (mild 
COVID-19), but 










Non–COVID-19 respiratory tract infection 
(30); Controls (143)
Decreased testosterone and increased LH 

























Outpatients negative for COVID-19 (20) No difference for testosterone, LH or FSH 
between positive and negative COVID-19 
patients; decreased testosterone in 
patients with COVID-19 pneumonia 
compared to COVID-19 without 
pneumonia
–








SARS-CoV-2 pneumonia who remained 
stable (6) or improved (21)
Decreased total and free testosterone in 
patients who had worsened or died 
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succumbed to COVID-19 while they remained positive 
for nasopharyngeal tests. This is supported by a post- 
mortem investigation of a 67-year-old male, reporting 
a negative test on the testis samples studied [36].
SARS-CoV-2 and semen quality
Two studies were found that primarily investigated the 
impact of SARS-CoV-2 infection on semen quality, 
reporting a negative impact on sperm quality (Table 
2). Li et al. [43] (2020) investigated 23 patients recover-
ing from COVID-19 infection in a hospital-based case- 
controlled cross-sectional study. This study reported 
that patients recovering from COVID-19 had signifi-
cantly decreased sperm concentration and increased 
seminal interleukin 6 (IL-6), TNF-α, and monocyte che-
moattractant protein-1 (MCP-1) compared to control. 
Furthermore, 39.1% patients had oligozoospermia and 
60.9% patients had increased leucocytes. Immune 
orchitis was also reported in some patients in this 
cohort. Maleki et al. [44] (2021) investigated 84 patients 
recovering from COVID-19 in a case-controlled long-
itudinal study compared to 105 healthy controls, with 
evaluations at 10-day intervals over a maximum fol-
low-up of 60 days. A significant reduction in semen 
volume, sperm concentration, progressive motility, 
and sperm morphology were reported. This was asso-
ciated with increased ACE2 enzyme activity in seminal 
plasma, increased seminal inflammation (IL-1β, IL-6, IL- 
8, IL-10, TGF-β, TNF-α, interferon α [IFN-α], IFN-γ), oxi-
dative stress (increased reactive oxygen species [ROS] 
and reduced superoxide dismutase [SOD]) and 
increased seminal apoptotic markers activity (cas-
pase-8, −9, and −3) compared to control.
An additional five studies included under the pre-
sence of viral RNA in semen also reported semen ana-
lysis results. In a case-controlled cohort study that 
included 16 patients recovering from COVID-19 
(mean [SD] age 42.2 [9.9] years), two patients with 
acute COVID-19 and 14 control patients (mean [SD] 
age 33.4 [13.1] years) that were negative for SARS- 
CoV-2, Holtmann et al. [37] (2020) reported that mod-
erate COVID-19 infection significantly reduced sperm 
concentration, progressive motility and total number 
of complete motility compared to men recovered from 
a mild infection and the control group. Semen para-
meters were found to be impacted in a case-controlled 
study of 74 men (median age 34 years) recovering from 
a confirmed infection, where 14.9% were asympto-
matic (mild), 41.9% were classified as moderate, and 
43.2% had severe pneumonia. Sperm concentration, 
total sperm count, and total motility were affected, 
but not volume or progressive motility. Only sperm 
concentration showed a correlation with disease sever-
ity, and longer recovery times (>90 days) also had 
significantly lower sperm concentration that shorter 
recovery (<90 days) [33]. Of 23 men (age range 20– 
62 years) in acute or convalescence stage of COVID-19, 
all patients had total sperm count, total motility and 
morphology within normal parameters [40]. In a case- 
controlled cross-sectional study that included con-
firmed and suspected COVID-19 cases pre-treatment 
(n= 10) and post-treatment (n= 10) to a healthy control 
group (n= 10), no significant differences in semen 
parameters were reported. However, normal sperm 
morphology was found to be reduced in the pre- 
treatment group compared to control, but this was 
not observed post-treatment [35]. Gacci et al. [29] 
(2021) reported in a cross-sectional cohort of sexually 
active men that were confirmed to be recovered from 
COVID-19 (n= 43) that 25% where found to be oligo- 
crypto-azoospermic, and this was related to severity of 
COVID-19 infections, exceeding the rates of found in 
the average population. Additionally, this study 
reported increased seminal IL-6 in 76% of the cohort, 
further suggesting that reproductive tract inflamma-
tion may be associated with COVID-19 infections in 
males. Furthermore, Ma et al. [30] (2021) reported 
a cohort of 12 COVID-19 male patients, where 66.7% 
of the patients had normal sperm parameters and low 
sperm DNA fragmentation (SDF), whereas 33.3% of the 
patients had low sperm motility with higher SDF.
SARS-CoV-2 on testicular histology
The present review identified five studies that reported 
testicular histology or US outcomes in patients 
infected with COVID-19 (Table 3).
Flaifel et al. [42] (2021) investigated testes and epi-
didymis specimens from 10 patients (age range 23– 
83 years) who had succumbed to COVID-19 following 
positive nasopharyngeal swabs for viral RNA at time of 
admission to hospital. Each patient had one or more 
comorbidities, including type 2 diabetes mellitus and 
hypertension, and remained positive for viral RNA in 
the nasopharyngeal tract but not the testicular sam-
ples at autopsy. The authors found that seven COVID- 
19 samples had morphological changes consistent 
with oxidative stress, including altered chromatin con-
densation, acidophilic cytoplasm, and DNA fragmenta-
tion. Spermatocytes were also found to be sloughed 
into the tubules in the epididymis. Furthermore, the 
Sertoli cells showed cellular swelling and vacuolisation. 
In cases that had a longer duration, hypertrophy of the 
tubular basement membrane and reduced intratubular 
cell mass was reported. Interestingly, two cases also 
showed signs of multiple microthrombi, associated 
with increased platelets in the testicular tissues. Only 
one case showed signs compatible with orchitis, 
namely influx of cluster of differentiation 8 (CD8)- 
positive dominated mononuclear leucocytes into the 
interstitial space.
Ma et al. [45] (2021) examined testicular tissue in five 
males who had died from COVID-19 complications (age 
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range 51–83 years) and compared these to non-COVID 
-19 (age range 71–80 years) affected testicular samples. 
All five COVID-19 patients all showed degenerated germ 
cells (GCs) sloughed off in the seminiferous tubules, 
whereas the controls showed normal GC development 
within the seminiferous tubules. They observed that two 
patients showed almost no GCs, appearing similarly to 
Sertoli cell-only syndrome. The patients with COVID-19 
also showed reduced DDX4-positive GC needed for reg-
ulation of GC proliferation and differentiation. However, 
there was no difference found with Sertoli cells between 
patients and controls. SARS-CoV-2 may therefore impair 
GC development, but not affect the Sertoli cells.
Achua et al. [31] (2021) analysed testicular specimens 
on autopsy from six COVID-19-positive males (age range 
20–87 years) compared to three COVID-19-negative 
controls (age range 28–77 years), with all patients hav-
ing relevant comorbidities. It was observed that three of 
the COVID-19 cases showed impaired spermatogenesis. 
Only one case reported infiltration of macrophages and 
lymphocytes within the testicular tissues. All other cases 
did not show any signs of inflammation. Interestingly, in 
the three patients with COVID-19 with normal sperma-
togenesis, ACE2 receptor expressions was significantly 
lower compared to the patients with COVID-19 with 
impaired spermatogenesis. The patients with impaired 
spermatogenesis and reduced ACE2 receptor expres-
sion also showed Sertoli cell-only syndrome, early 
maturation arrest, and sclerosis of the seminiferous 
tubules.
Yang et al. [46] (2020) analysed 11 patients’ testes 
on autopsy who had died from COVID-19 (age range 
42–87 years), where 10 of these patients had a history 
of fever, and 10 received low-dose steroidal therapy. 
This was compared to five uninfected control autopsy 
cases negative, for COVID-19 Sertoli cells were most 
notably affected by ‘ballooning’ morphological 
changes, with swelling and hydrolysation alongside 
detachment from the basement membrane. These 
findings were classified as 18.2%, 45.5%, and 36.4% of 
11 cases showing mild, moderate, and several injuries, 
respectively, compared to controls that showed no 
injuries or mild tubular derangements only. In addi-
tion, Leydig cell counts in COVID-19 cases was signifi-
cantly reduced compared to the controls. Furthermore, 
there was oedema and mild inflammatory cellular 
influx.
Chen et al. [47] (2020), in a retrospective study of 
a cohort of 142 confirmed COVID-19-positive patients 
(age range 24–93 years), examined US reports made at 
the bedside. These cases were classified as mild or 
moderate (41.9%) and severe or critical (58.5%), with 
the latter group significantly older and more likely to 
have coronary heart disease or chronic obstructive 
pulmonary disease compared to the mild/moderate 
group. Acute orchitis was present in 10% of all 
patients, with 7% presenting with acute epididymitis, 
and 15% presenting with acute epididymo-orchitis. 
Additional manifestations observed in all patients was 
a thickened tunica albuginea (25.4%), increased testi-
cular vascular flow (20,4%), increased epididymal vas-
cular flow (16,9%), heterogeneous echogenicity of 
testis (9.9%), scrotal swelling (8.5%), enlargement of 
epididymis (7.7%), hydrocele (7,7%), enlargement of 
testis (7%), heterogeneous echogenicity of epididymis 
(5.6%), and abscesses in the epididymis (2.8%). Severe 
and critical cases had significantly increased percen-
tage of patients with thickened tunica albuginea, het-
erogeneous echogenicity of the testis, increased 
testicular and epididymal vascular flow and absence 
in the epididymis compared to mild and moderate 
cases. Importantly, there was an increased risk of scro-
tal infection within this age group of the cohort.
Additional information is reported in a study cate-
gorised under semen quality, where Li et al. [43] (2020) 
reported testicular damage in six age-matched case- 
controlled autopsies on testicular tissue. This included 
inflammatory infiltration into testicular and epididymal 
tissue, signs of oedema, congestion and red blood cell 
exudates. The seminiferous tubules were thinned with 
an increased number of apoptotic cells were present, 
as well as increased CD3+ and CD68+ in the interstitial 
cells of testicular tissue and the presence of immuno-
globulin G (IgG) within seminiferous tubules of autop-
sied testes. Furthermore, Song et al. [36] (2020) 
reported that there was no detection of SARS-CoV-2 
viral RNA in the testis of an autopsied 67-year-old male 
who had succumbed to COVID-19.
SARS-CoV-2 on testicular clinical presentations
There were two studies primarily reporting testicular 
clinical symptoms in COVID-19 infections (Table 4). 
Patients aged between 18 and 75 years diagnosed 
with COVID-19 (n= 91) were evaluated for testicular 
pain or epididymo-orchitis. Here, 11% of patients pre-
sented with pain, and only one was clinically diag-
nosed with epididymo-orchitis. Subsequent 
comparison of patients with the presence (n = 10) or 
absence (n = 81) of testicular pain showed no differ-
ence for neutrophil count, lymphocyte count, 
C-reactive protein (CRP), D-dimers or duration of 
COVID-19 infection between these groups, where lym-
phopenia was significantly more common in older 
patients, but not testicular pain or swelling [48]. Kim 
et al. [49] (2020) reported the case of 42-year-old adult 
male presenting in the emergency room with severe 
abdominal pain and testicular pain, without respiratory 
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symptoms, that was subsequently diagnosed with 
COVID-19. In a cohort of 34 male patients recovering 
from COVID-19, Pan et al. [34] (2020) reported 
a prevalence of 19% for symptoms indicative of 
orchitis.
SARS-CoV-2 infection and male reproductive 
hormones
There were two studies primarily reporting reproduc-
tive outcomes in COVID-19 infections (Table 5). 
Kadihasanoglu et al. [50] (2020) conducted a case- 
controlled cross-sectional study on 89 patients classi-
fied as hospitalised for confirmed COVID-19 (mean [SD] 
age 49.9 [12.5] years), 30 hospitalised cases with non– 
COVID-19 (two or more negative tests) respiratory tract 
infection (mean [SD] 52.7 [9.6] years) and 143 age- 
matched controls (mean [SD] 50 [7.8] years). The 
COVID-19 cohort was described as mild (52.8%), mod-
erate (33.7%) and severe (13.5%). Testosterone was 
significantly lower, and LH and prolactin were higher 
in the COVID-19 cohort compared to non-COVID-19 
infections and control groups, with no differences 
between groups for FSH. Furthermore, patients with 
COVID-19 reported significantly lower white blood cell 
count (WBC) and lymphocyte count and higher CRP 
compared to controls, where WBC and lymphocytes, 
but not CRP, were significantly increased in patients 
with COVID-19 compared to non-COVID-19 patients. 
These variables were found to be associated with the 
severity of disease and were further significantly worse 
in patients classified as severe COVID-19. Testosterone 
also negatively correlated with hospital duration and 
positively correlated with oxygen saturation in patients 
with COVID-19, but not in the non-COVID-19 infection 
group. No correlations were found for testosterone 
compared to neutrophil count, lymphocyte count or 
CRP. In four patients who succumbed to COVID-19, the 
testosterone levels of these cases was below the med-
ian for the COVID-19 cohort [50].
Ma et al. [30] (2021) investigated 119 male patients 
(age range 20–49 years) for reproductive hormones, 
where all patients had a stable clinical status during 
the study in the hospital setting. This was compared to 
273 age-matched controls (age range 24–49 years) 
who were undergoing reproductive hormonal analysis 
for fertility prior to marriage or planning parenthood. 
The COVID-19 cohort was described as mild (84.0%), 
moderate (11.8%) and severe (1.96%), and case man-
agement included use of corticosterone (14.8%), arbi-
dol (45.3%), oseltamivir (33.6%), or intravenous 
antibiotics (56.3%). In 39% of the cases liver function 
(elevated alanine aminotransferase [ALT] and aspartate 
aminotransferase [AST]) was impaired. The reproduc-
tive hormonal analysis showed that LH was signifi-
cantly higher in the COVID-19 cohort compared to the 
control, whereas no difference in testosterone, FSH 
and oestrogen levels were found between groups.
Okçelik et al. [51] (2020) studied 44 patients (mean-
[SD] age 35.5 [9.9} years) in a COVID-19 outpatient 
clinic. Testosterone, LH and FSH were not significantly 
different in patients who tested positive for COVID-19 
(n = 24) compared to negative patients (n = 20). In 42 
patients that had a chest CT scan, COVID-19 pneumo-
nia was diagnosed in 23. Testosterone was significantly 
lower in the pneumonia group compared to those 
without pneumonia.
Rastrelli et al. [52] (2020) investigated 31 patients 
recovering from SARS-CoV-2 pneumonia in the respira-
tory intensive care unit of Carlo Poma Hospital, 
Mantua, Italy. It was found that 67.7% improved in 
clinical presentation (age range 55–66 years), 19.4% 
remained stable (age range 33–83 years) and 12.9% 
worsened or died (age range 59–85 years) at time of 
analysis. There was a significantly lower total and free 
testosterone and higher LH in the severe/deceased 
group compared to the other groups. These patients 
also reported significantly increased CRP, procalcitonin 
and neutrophil count with lower lymphocytes. The 
authors concluded that lower baseline levels of testos-
terone predict mortality outcomes in patients with 
SARS-CoV-2 infections that are in intensive care units.
Discussion
Initial fears of a negative impact of SARS-CoV-2 infec-
tion on male fertility resulted in many couples delaying 
pregnancy and fertility treatment, although many have 
now resumed their pursuit of parenthood and are 
accepting the uncertainty [22]. Guidelines for assisted 
reproductive technology (ART) management have also 
been issued by professional societies such as the 
American Society for Reproductive Medicine (ASRM), 
European Society of Human Reproduction and 
Embryology (ESHRE) and International Federation of 
Fertility Societies (IFFS) [53], with concerns raised on 
impact and transmission of the virus on fertility and 
ART [54,55]. This has included recommendation for 
gonadal function assessment and semen analysis in 
males of reproductive age who have recovered from 
COVID-19 [56]. There is a further concern that SARS- 
CoV-2 may be transmitted sexually, or via ART 
[22,23,25], which requires the presence of the virus in 
seminal or vaginal fluids for such a mode of transmis-
sion [57].
SARS-CoV-2 gains access to cells via ACE2 receptor 
binding with TMPRSS2 priming [7,8]. The testes are 
reported to express ACE2, particularly in the sperma-
togonia, Leydig cells and Sertoli cells, which leads to 
the hypothesis of SARS-CoV-2 gaining access to 
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testicular tissues and seminal fluid, directly affecting 
male reproductive health [58]. TMPRSS2 has been 
reported to be present in prostate epithelial cells, 
where the expression is regulated by androgens, and 
present in semen as components of prostasomes 
[59,60]. These proteasomes or the ‘exosome-like struc-
tures’ reportedly may incorporate TMPRSS2 in the 
sperm membrane [60]. Therefore, although ACE2 is 
expressed in male reproductive tissues, there is gener-
ally a lack of TMPRSS2 modulatory protein co- 
expression except in prostatic epithelial cells [57,59], 
and the presence of ACE2 and TMPRSS2 together in 
male reproductive tissues is considered relatively 
low [24].
Although ACE2 receptors are found to be expressed 
in male reproductive tissue, specifically the testis [58], 
and TMPRSS2 has been reported to be present in 
prostate epithelial cells and in semen [59,60], it is still 
not clear whether SARS-CoV-2 does gain access 
directly to the male reproductive tract. In an early 
systematic review, Khalili et al. [27] (2020) reported 
that the virus may be present in seminal fluid, with 
limited evidence of reduced semen parameters and 
testosterone. Yao et al. [61] (2021) concluded that 
there is limited evidence for the virus in seminal fluid; 
however, fatal cases appear to have damaged testicu-
lar structures in the absence of the virus. A subsequent 
systematic review investigating viral presence of SARS- 
CoV-2 in male and female reproductive tracts con-
cluded that the virus is unlikely to be considered 
a sexually transmitted virus. This included semen, tes-
ticular biopsies, prostatic fluid, vaginal fluids, and 
oocyte samples. However, the induction of orchitis, or 
having an impact on spermatogenesis and semen ana-
lysis findings or testosterone level is still possible [57]. 
These results are generally consistent with the results 
of this systematic review, where there is little evidence 
suggesting viral presence in the seminal fluid or repro-
ductive tract. There is also little evidence to suggest 
SARS-CoV-1 is present in seminal fluid [62–64]. 
Therefore, the evidence for sexual transmission is also 
currently lacking, particularly as the presence of viral 
nucleic acids in seminal fluid does not equate to an 
infectious intact virus [64].
Although there have been 27 viruses reported to 
gain access to semen through viraemia, including 
Hepatitis B and C, Adenovirus, HIV, Mumps, Ebola, 
Zika and numerous herpes family viruses reported in 
seminal fluid [62–64], the seemingly low risk of SARS- 
CoV-2 presence in seminal fluid may be due to the low 
levels of both ACE2 and TMPRSS2 expressed in the 
testis [24]. Pan et al. [34] (2020) suggested that ACE2 
mediated viral entry into target cells is unlikely to occur 
within the human testis as single-cell transcriptome 
analysis demonstrates sparse expression of ACE2 and 
TMPRSS2. Further evidence supporting this is from 
a retrospective cohort study using cryopreserved 
semen samples obtained from young healthy adult 
sperm donors at the Hunan Province Human Sperm 
Bank (China), where paired blood and semen samples 
from 50 donors during the first wave of the pandemic, 
and 50 donors collected upon work resumption, where 
analysed. This study reported that all samples from 
during and after the pandemic wave were free of SARS- 
CoV-2 detection and safe for external use [65].
The 27 viruses detected in human semen all come 
from diverse families, suggesting that mechanisms for 
viral access may not be unique to specific viral epi-
topes. Non-specific mechanisms could be through 
serum viral load, inflammatory mediators altering the 
blood–testis barrier (BTB), testicular immunosuppres-
sion that may protect viruses from testicular immune 
surveillance, and pyrexia [54,62,64,66]. The few 
accounts of the presence of SARS-CoV-2 may be 
through a BTB breach, and may account for subse-
quent damage to GCs and testicular interstitial tissues 
[24]. However, there are still too few studies for appro-
priate conclusions in COVID-19, and these studies cur-
rently have small sample sizes, and mostly confined to 
men with mild-to-moderate symptoms.
Reproductive tract inflammation and infections are 
causes of male infertility, most prominently bacterial 
infections, environmental causes and autoimmunity 
[66]. This may also include systemic autoimmune dis-
ease and chronic asymptomatic inflammation asso-
ciated with obesity, metabolic syndrome and 
diabetes mellitus [67,68]. It is known that viral infec-
tions may negatively affect fertility, including adeno-
virus, herpes simplex virus, HIV, hepatitis B and 
C [63,69–71]. More recently, in was reported that the 
Zika virus may also alter semen parameters and reduce 
male fertility [63,64]. Although there remains a paucity 
of studies, there is current evidence for impaired sperm 
parameters in COVID-19, mostly in males recovering 
from infection. This is consistent with the review con-
ducted by Meng et al. [72] (2020), suggesting that 
SARS-CoV-2 can cause spermatogenesis dysfunction 
and impaired sperm parameters. However, as there is 
little evidence suggesting the presence of the virus in 
reproductive tissues, this is most likely mediated by 
non-specific mechanisms. The viral-induced damage 
is proposed through changes to testicular structure 
and/or function, immune cell infiltration into the testi-
cular compartment, a systemic inflammatory response, 
pyrexia, reduced testosterone, and potential incor-
poration of the virus genetic material into the GC 
genome [63,66,69].
Although inflammatory cytokines such as TNF-α, IL- 
1β, and IL-6 have physiological functions, increased 
levels with inflammation can negatively impact sper-
matogenesis. Inflammation is also typically associated 
with oxidative stress [67,73]. Males are also commonly 
found to have acute or chronic inflammation of the 
reproductive tract in an infertility assessment [67,73]. 
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Effects of acute febrile illness induced in rats showed 
impaired spermatogenesis and increased GC apoptosis 
that was not consistent with hormonal changes, sug-
gesting direct impact of the immune response [74]. 
GCs have also been shown to have receptors for TNF, 
IL-1 and IL-6, supporting a direct action of these cyto-
kines in the induction of apoptosis [75]. Furthermore, 
febrile illness due to viral infection, including influenza 
and SARS-CoV-1, is known to negatively impact sperm 
parameters, including concentration, motility, and 
morphology [63]. Based on the limited evidence avail-
able, it is likely that inflammation and oxidative stress 
associated with COVID-19 may negatively impact sper-
matogenesis. This is supported by histological studies 
suggesting inflammatory and oxidative stress 
mediated damage. Therefore, clinical investigation for 
males recovering from COVID-19 may be warranted, as 
well as consideration in the clinical assessment of 
infertile males. Furthermore, the current evidence 
may warrant the consideration of cryopreservation in 
ART patients at high risk of SARS-CoV-2 exposure or 
a severe clinical course of COVID-19, particularly as 
long-term reversibility is not yet established.
Numerous viruses that cause viraemia have been asso-
ciated with orchitis, including influenza, Coxsackie B, SARS- 
CoV-1, rubella, smallpox, echovirus, and parvovirus [62– 
64]. Mumps orchitis is arguably the most well-known viral 
disease that can be complicated with orchitis in males, and 
may cause testicular atrophy and infertility [76]. 
Furthermore, orchitis was found to be a complication of 
SARS-CoV-1 viral infections [77]. The limited results of the 
present review suggest that orchitis is a possible compli-
cation in COVID-19. Viral orchitis is associated with infiltra-
tion of neutrophils, macrophages and T and 
B lymphocytes, with degeneration of germinal epithelium 
and few to no spermatogonia and Sertoli cells, lamina 
propria hypertrophy and fibrosis of the tubules. 
However, Leydig cells generally do not show signs of 
cellular injury [66]. Orchitis and histological damage to 
testicular tissues in COVID-19 may further be mediated 
by a vasculitis, as hypercoagulability and the segmental 
vascularisation structure of the testis may induce inflam-
mation [56]. This is consistent with evidence of testicular 
autopsy in patients with severe phase 2 infection who 
ultimately died. This was also reported for SARS-CoV-1 
autopsy specimens of patients (n= 6) that had died, 
where the testes also showed GC destruction, few sper-
matozoa in the seminiferous tubules, basement mem-
brane hypertrophy, leucocyte infiltration (CD3+ 
T lymphocytes and CD68+ macrophages) and IgG precipi-
tation in seminiferous epithelium. This was also without 
detection of SARS-CoV-1 genomic sequences in the sam-
ples, further supporting immune-mediated damage to 
testicular tissues [77].
Although there are studies suggesting female pre-
dominance or no sex disparity, there is increasing evi-
dence of a male predominance for COVID-19 morbidity 
and mortality [10,12]. In a meta-analysis, Peckham et al. 
[13] (2020) reported no difference between male and 
female gender for confirmed infections, where males 
were reported to have a 2.84 increased risk of intensive 
care treatment and 1.39 increased risk of death. Similar 
increased sex differences in COVID-19 fatality has been 
reported in data from Europe, China and Korea [14–17]. 
Moreover, observational studies further report that the 
severity of COVID-19 intensive care and mortality rates 
are increased in males [18,19]. This has also been found 
to be similar regarding retrospective data that was 
retrieved from patients with SARS-CoV-1 [16]. Males 
may also shed the SARS-CoV-2 virus for longer dura-
tion compared to females [78]. This has led to the 
suggestion that androgens may be involved in the 
pathogenesis of COVID-19.
Testosterone is known to be reduced in comorbidities 
associated with COVID-19, including ageing, obesity, dia-
betes and chronic obstructive pulmonary disease [79]. 
Hypogonadism is further associated with increased inflam-
matory cytokines, and testosterone reduces IL-1β, IL-6, and 
TNF-α, which is accentuated in ageing. Although only four 
studies are included that investigated androgens in 
patients with COVID-19, the results of this review suggest 
that testosterone may be reduced in male patients with 
COVID-19 compared to controls, and this is negatively 
associated with CRP as a systematic marker of inflamma-
tion. Furthermore, in a non-peer reviewed published 
article, Schroeder et al. [80] (2020) reported that 
68.6% of males with COVID-19 in intensive care 
units (Hamburg, Germany) had lower serum testos-
terone levels and 48.6% had lower dihydrotestoster-
one levels, which was negatively correlated with 
severity and death. Lower testosterone was nega-
tively correlated with IL-2 and INF-γ, and oestradiol 
positively correlated with IL-6, as did disease sever-
ity. Reduced testosterone may therefore be involved 
in the pathogenesis of the cytokine storm and com-
plications of phase 2 COVID-19 [79]. This reduced 
testosterone may further weaken respiratory mus-
cles and reduce lung function parameters such as 
forced expiratory volume [79]. However, female 
patients may be generally less susceptible to viral 
infections through a better immune response due 
to the activity of oestrogen in activating T cells, 
a reduced expression of inflammatory cytokines, 
and increasing antibody formation in B-lymphocyte 
humoral immune response [12]. Male patients also 
have higher expression of ACE2 in the renal system 
compared to females, which may further explain 
a gender disparity [12].
Conclusion
There is little evidence suggesting SARS-CoV-2 viral 
presence in the male reproductive tract and that 
sexual transmission may occur. However, COVID-19 
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infections may have a negative impact on sperma-
togenesis and male fertility. The current evidence 
available suggests that non-specific mechanisms 
associated with the systemic and local reproductive 
immune response to the SARS-CoV-2 virus could 
explain the impact. This may also be associated 
with orchitis and associated testicular ultrasonogra-
phy changes. COVID-19 may further decrease tes-
tosterone, which in turn exacerbates the 
inflammatory response. The clinical evaluation of 
male reproductive tract, seminal parameters and 
reproductive hormones are recommended in men 
undergoing fertility treatment. Any long-term nega-
tive impact on male reproduction remains unex-
plored and requires further future consideration.
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